You are here

Clever Drugs for Slimy Bugs

A new way to fight staph infections

Staphylococcus aureus bacteria attach to catheters, artificial joints, implants, and patients' burns and wounds, establishing bacterial biofilms, a leading cause of failing antibiotic therapies and chronic infections. But Queensland University of Technology researchers have developed hybrid antibiotics designed to penetrate the slimy shield protecting invasive staph infections.

"Biofilms are a sticky, slimy coating that often prevents conventional antibiotics from accessing bacterial cells," says PhD student Anthony Verderosa, who co-led the study with associate professor Makrina Totsika. "We have developed a new breed of antibiotic that tricks biofilms into releasing their protected cells, allowing access through the protective coating.”

The microscopic compound emits a fluorescence signal, allowing researchers to watch the drug penetrating the biofilm, either killing the bacteria directly or leaving them susceptible to killing.

"What is promising is the fact that our compounds are hybrids of drugs that are already in clinical use as stand-alone therapies, such as conventional antibiotics and nitroxides,” Dr. Totsika says, “so this offers hope that they could be translated into clinical therapies in the not-so-distant future."

Source: ScienceDaily, December 2, 2019.

Recent Headlines

Study finds fewer than half of trials followed the law
WHO to meet tomorrow to decide on international public heath emergency declaration
Study of posted prices finds wild variations and missing data
Potential contamination could lead to supply chain disruptions
Despite older, sicker patients, mortality rate fell by a third in 10 years
Declining lung cancer mortality helped fuel the progress
Kinase inhibitor targets tumors with a PDGFRA exon 18 mutation
Delayed surgery reduces benefits; premature surgery raises risks
Mortality nearly doubled when patients stopped using their drugs